16
APR
2013
NW Bio’s Phase III Trial With DCVax®-L For Brain Cancer “Adopted” As A National Priority Trial In UK
Comments : Off
Trial Sites Will Receive Support from UK Health System BETHESDA, Md., April 16, 2013 — Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Company’s Phase III clinical trial for Glioblastoma multiforme (GBM) brain cancer has been “adopted” as a national priority trial in the UK, under the... Read More